RESUMEN
The increasing worldwide prevalence of metabolic syndrome (MetS), especially in younger populations, is a risk factor for fertility disorders. However, a direct correlation of MetS with male infertility still remains unclear. In this work, we evaluated whether MetS has a negative impact on fertility of hybrid male mice with high reproductive performance. To induce a MetS-like condition, (C57BL/6xBALB/c) F1 male mice were fed a high-fat diet (HFD, 30% fat) for 19 weeks, while controls received a normal-fat diet (NFD, 6% fat). HFD-fed animals exhibited increased body weight, hypercholesterolemia, hyperglycemia and glucose intolerance. In vivo fertilisation assays performed along the treatment period showed no differences in fertilisation nor in vitro embryo development rates between groups. While testicular weight and morphology were similar in both groups, HFD-fed mice presented lighter epididymides and higher amounts of gonadal fat. Moreover, sperm count was lower in HFD-fed mice, despite normal sperm viability, morphology, motility or acrosome reaction. Finally, no differences were observed in in vitro fertilisation rates between groups. In summary, although HFD feeding altered some reproductive parameters, it did not impair male fertility in high performance breeders suggesting the possibility that a fertility impairment could be the result of the cumulative combination of environmental and/or genetic factors.
Asunto(s)
Dieta Alta en Grasa/efectos adversos , Fertilidad/fisiología , Infertilidad Masculina/diagnóstico , Síndrome Metabólico/complicaciones , Espermatozoides/fisiología , Reacción Acrosómica , Animales , Supervivencia Celular/fisiología , Modelos Animales de Enfermedad , Femenino , Humanos , Infertilidad Masculina/etiología , Infertilidad Masculina/fisiopatología , Masculino , Síndrome Metabólico/etiología , Síndrome Metabólico/fisiopatología , Ratones , Recuento de Espermatozoides , Motilidad Espermática/fisiología , Testículo/fisiologíaRESUMEN
BACKGROUND: Loss or mutations of the BRCA1 gene are associated with increased risk of breast and ovarian cancers and with prostate cancer (PCa) aggressiveness. Previously, we identified GADD153 as a target of BRCA1 protein, which increases doxorubicin sensitivity in human p53 -/- PCa cells (PC3). Considering that p53 is a crucial target in cancer therapy, in this work we investigated p53 role in the regulation of transcription of GADD153. METHODS: We performed reverse transcription quantitative PCR (RT-qPCR), western blot and luciferase assays to analyze GADD153 and/or BRCA1 expression in response to ultraviolet or doxorubicin exposure in PC3 p53 stable-transfected cells and LNCaP (p53+/+) cells. BRCA1 protein recruitment to GADD153 promoter was studied by chromatin immunoprecipitation-qPCR. To assess expression of BRCA1 and/or p53 target genes, we used a panel of stable-transfected PCa cell lines. We finally analyzed these genes in vivo using BRCA1-depleted PCa xenograft models. RESULTS: We found that GADD153 was highly induced by doxorubicin in PC3 cells; however, this response was totally abolished in LNCaP (p53wt) and in p53-restituted PC3 cells. Furthermore, BRCA1 protein associates to GADD153 promoter after DNA damage in the presence of p53. Additionally, we demonstrated that BRCA1 and/or p53 modulate genes involved in DNA damage and cell cycle regulation (cyclin D1, BLM, BRCA2, DDB2, p21(WAF1/CIP1), H3F3B, GADD153, GADD45A, FEN1, CCNB2), EMT (E-cadherin, ß-catenin, vimentin, fibronectin, slug, snail) and Hedgehog pathways (SHH, IHH, DHH, Gli1, PATCH1). Furthermore, xenograft studies demonstrated that BRCA1 knockdown in PC3 cells increased tumor growth and modulated these genes in vivo. CONCLUSIONS: Although BRCA1 induces GADD153 in a p53 independent manner, p53 abolished GADD153 induction in response to DNA damage. In addition, several important PCa targets are modulated by BRCA1 and p53. Altogether, these data might be important to understand the therapy response of PCa patients.
Asunto(s)
Proteína BRCA1/metabolismo , Neoplasias de la Próstata/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Animales , Proteína BRCA1/genética , Ciclo Celular/genética , Línea Celular Tumoral , Daño del ADN , Erizos/genética , Erizos/metabolismo , Xenoinjertos , Humanos , Masculino , Ratones , Neoplasias de la Próstata/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Factor de Transcripción CHOP/metabolismo , Transcripción Genética , Proteína p53 Supresora de Tumor/genéticaRESUMEN
BACKGROUND: Organ confined prostate cancer (PCa) can be cured by radical retropubic prostatectomy (RRP); however, some tumors will still recur. Current tools fail to identify patients at risk of recurrence. Glutathione-S-transferases (GSTs) are involved in the metabolism of carcinogens, hormones and drugs. Thus, genetic polymorphisms that modify the GST activities may modify the risk of PCa recurrence. METHODS: We retrospectively recruited Argentine PCa patients treated with RRP to study the association between GST polymorphisms and PCa biochemical relapse after RRP. We genotyped germline DNA in 105 patients for: GSTP1 c.313A>G (p.105 Ile>Val, rs1695) by PCR-RFLP; and GSTT1 null and GSTM1 null polymorphisms by multiplex PCR. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate these associations. RESULTS: Patients with GSTP1 c.313GG genotype showed shorter biochemical relapse-free survival (BRFS) (P = 0.003) and higher risk for recurrence in unadjusted (Hazard ratio (HR) = 3.16, 95% confidence interval (95% CI) = 1.41-7.06, P = 0.005) and multivariate models (HR = 3.01, 95% CI = 1.13-8.02, P = 0.028). We did not find significant associations for GSTT1 and GSTM1 genotypes. In addition, we found shorter BRFS (P = 0.010) and increased risk for recurrence for patients having two or more risk alleles when we combined the genotypes of the three GSTs in multivariate models (HR = 3.06, 95% CI = 1.20-7.80, P = 0.019). CONCLUSIONS: Our results give support to the implementation of GSTs genotyping for personalized therapies as a novel alternative for PCa management for patients who undergo RRP. To the best of our knowledge, this is the first study that examined GST polymorphisms in PCa progression in Argentine men. Replication of our findings in larger cohort is warranted.
Asunto(s)
Predisposición Genética a la Enfermedad/genética , Glutatión Transferasa/genética , Recurrencia Local de Neoplasia/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Anciano , Estudios de Casos y Controles , Genotipo , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Recurrencia Local de Neoplasia/mortalidad , Estadificación de Neoplasias , Reacción en Cadena de la Polimerasa , Polimorfismo de Nucleótido Simple , Modelos de Riesgos Proporcionales , Prostatectomía , Neoplasias de la Próstata/cirugía , Factores de RiesgoRESUMEN
It is currently estimated that inflammatory responses are linked to 15-20% of all deaths from cancer worldwide. Although many studies point to an important role of inflammation in prostate growth, the contribution of inflammation to castration-resistant prostate cancer is not completely understood. The presence of inflammatory mediators in tumor microenvironment raises the question whether genetic events that participate in cancer development and progression are responsible for the inflammatory milieu inside and surrounding tumors. Activated oncogenes, cytokines, chemokines and their receptors, sustained oxidative stress and antioxidant imbalance share the capacity to orchestrate these pro-inflammatory programs; however, the diversity of the inflammatory cell components will determine the final response in the prostate tissue. These observations give rise to the concept that early genetic events generate an inflammatory microenvironment promoting prostate cancer progression and creating a continuous loop that stimulates a more aggressive stage. It is imperative to dissect the molecular pathologic mechanism of inflammation involved in the generation of the castration-resistant phenotype in prostate cancer. Here, we present a hypothesis where molecular signaling triggered by inflammatory mediators may evolve in prostate cancer progression. Thus, treatment of chronic inflammation may represent an important therapeutic target in advanced prostate cancer.
Asunto(s)
Mediadores de Inflamación/metabolismo , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Animales , Huesos/metabolismo , Huesos/patología , Quimiocinas/metabolismo , Progresión de la Enfermedad , Humanos , Inflamación/metabolismo , Inflamación/patología , Masculino , Metástasis de la Neoplasia/genética , Estadificación de Neoplasias , Estrés Oxidativo , Neoplasias de la Próstata/genética , Especies Reactivas de Oxígeno/metabolismo , Receptores de Quimiocina/metabolismo , Transducción de Señal , Microambiente Tumoral/genéticaRESUMEN
Prostate cancer (PCa) is the second leading cause of cancer-associated death in men. Once a tumor is established it may attain further characteristics via mutations or hypoxia, which stimulate new blood vessels. Angiogenesis is a hallmark in the pathogenesis of cancer and inflammatory diseases that may predispose to cancer. Heme oxygenase-1 (HO-1) counteracts oxidative and inflammatory damage and was previously reported to play a key role in prostate carcinogenesis. To gain insight into the anti-tumoral properties of HO-1, we investigated its capability to modulate PCa associated-angiogenesis. In the present study, we identified in PC3 cells a set of inflammatory and pro-angiogenic genes down-regulated in response to HO-1 overexpression, in particular VEGFA, VEGFC, HIF1α and α5ß1 integrin. Our results indicated that HO-1 counteracts oxidative imbalance reducing ROS levels. An in vivo angiogenic assay showed that intradermal inoculation of PC3 cells stable transfected with HO-1 (PC3HO-1) generated tumours less vascularised than controls, with decreased microvessel density and reduced CD34 and MMP9 positive staining. Interestingly, longer term grown PC3HO-1 xenografts displayed reduced neovascularization with the subsequent down-regulation of VEGFR2 expression. Additionally, HO-1 repressed nuclear factor κB (NF-κB)-mediated transcription from an NF-κB responsive luciferase reporter construct, which strongly suggests that HO-1 may regulate angiogenesis through this pathway. Taken together, these data supports a key role of HO-1 as a modulator of the angiogenic switch in prostate carcinogenesis ascertaining it as a logical target for intervention therapy.
Asunto(s)
Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Hemo-Oxigenasa 1/farmacología , Neovascularización Patológica/tratamiento farmacológico , Neoplasias de la Próstata/irrigación sanguínea , Análisis de Varianza , Animales , Cartilla de ADN/genética , Hemo-Oxigenasa 1/metabolismo , Técnicas Histológicas , Humanos , Inmunohistoquímica , Luciferasas , Masculino , Ratones , Ratones Desnudos , Neovascularización Patológica/patología , Plásmidos/genética , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor A de Crecimiento Endotelial Vascular/metabolismo , Factor C de Crecimiento Endotelial Vascular/metabolismoRESUMEN
The metastatic cascade and colonization remains a major challenge in clinical therapeutics. The formation of metastasis has many rate limiting steps. The expression of metastases initiation genes in primary tumors is driven by the need for cell motility, invasiveness, handling the shear stress in the vasculature and lymphatic circulation, and the survival and persistent growth in the distant organ. However, the expression of the progression genes in the primary tumors has a more complex basis. These metastasis-prone genes support primary tumor growth through one particular effect, whereas they enhance distant metastasis through another effect. The boundaries between metastasis initiation and metastasis progression genes are not rigid. In this review, we examine novel gene signatures identified in metastases, address key inflammatory factors mastering homing selection, gain further mechanistic insights into cell plasticity and evaluate the role of microRNAs. Moreover, we also describe the recent progress in developing nanoparticle imaging substantiating a promising theranostic platform for future cancer diagnostics and treatment, and assess the relevance of the bioinformatic analysis of metastasis-related proteins with an eye toward the metastatic niche. All these tools will provide valuable biological information of the progression of the disease, helping find potential therapeutic targets and improving surgical procedures. In a near future the understanding of the molecular mechanisms in tumor dissemination will be pivotal for the translation of these methods to the clinic and will help to overcome the barriers in clinical therapy of metastases.
Asunto(s)
Regulación Neoplásica de la Expresión Génica , Metástasis de la Neoplasia , Animales , Progresión de la Enfermedad , Transición Epitelial-Mesenquimal , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , MicroARNs/genética , Invasividad Neoplásica , Metástasis de la Neoplasia/tratamiento farmacológico , Metástasis de la Neoplasia/genética , Metástasis de la Neoplasia/inmunología , Metástasis de la Neoplasia/patología , Transducción de SeñalRESUMEN
The porphyrias are a group of inherited metabolic disorders of heme biosynthesis which result from a partial deficiency in one of its seven specific enzymes, after its first and rate limiting enzyme, delta-aminolevulinic acid synthetase. They can be classified on the basis of their clinical manifestations into cutaneous, acute and mixed disorders. Acute intermittent porphyria (AIP) is the most common type of hepatic acute porphyrias, inherited as an autosomal dominant trait, caused by a defect in the gene which codifies for the heme enzyme porphobilinogen deaminase. Its prevalence in the Argentinean population is about 1:125,000. A partial deficiency in another enzyme, protoporphyrinogen oxidase, produces variegate porphyria (VP), the second acute porphyria most frequent in the Argentinean population (1:600,000). Here, we review all the mutations we have found in 46 AIP and 9 VP unrelated Argentinean patients. To screen for mutations in symptomatic patients, we have proposed a geneticresearch strategy.
Asunto(s)
Porfiria Intermitente Aguda/genética , Porfirias Hepáticas/genética , Argentina , Humanos , Mutación , Porfiria Intermitente Aguda/epidemiología , Porfiria Intermitente Aguda/metabolismo , Porfirias Hepáticas/epidemiología , Porfirias Hepáticas/metabolismoAsunto(s)
Hidroximetilbilano Sintasa/genética , Porfiria Intermitente Aguda , Porfiria Intermitente Aguda/diagnóstico , Adolescente , Adulto , Anciano , Femenino , Genes Dominantes , Humanos , Masculino , Persona de Mediana Edad , Mutación , Análisis de Secuencia por Matrices de Oligonucleótidos , Reacción en Cadena de la Polimerasa , Porfiria Intermitente Aguda/enzimología , Porfiria Intermitente Aguda/etiología , Porfiria Intermitente Aguda/genética , Porfiria Intermitente Aguda/patologíaRESUMEN
A partial deficiency of Porphobilinogen deaminase (PBGD) is responsible for acute intermittent porphyria (AIP). AIP is inherited in an autosomal dominant fashion, and the prevalence in the Argentinean population is about 1:125,000. Here, two new mutations and two previously reported were found in the PBGD gene in 22 Argentinean AIP patients corresponding to 8 different families. To screen for AIP mutations in symptomatic patients, genomic DNA isolated was amplified in 6 PCR reactions, then all coding exons and flanking intronic regions were sequenced. The novel mutations are 841-843delGGA in exon 14, which results in the loss of glycine-281 (G281del), and one 104C>T point mutation in the exon 4 (T35M). To further characterize both novel mutations, the pKK-PBGD construct for the mutant alleles were expressed in E. coli, the enzymatic activity of the recombinant proteins were 1% and 4% of the mean level expressed by the normal allele for 841-843delGGA and T35M, respectively. Hum Mutat 16:373, 2000.
Asunto(s)
Hidroximetilbilano Sintasa/genética , Mutación Missense/genética , Porfiria Intermitente Aguda/enzimología , Porfiria Intermitente Aguda/genética , Eliminación de Secuencia/genética , Adolescente , Adulto , Niño , Femenino , Humanos , Masculino , Metionina/genética , Persona de Mediana Edad , Treonina/genéticaRESUMEN
Uroporphyrinogen decarboxylase (URO-D) deficiency is responsible for two forms of genetic cutaneous porphyria: familial porphyria cutanea tarda (f-PCT) and hepatoerythropoietic porphyria (HEP). The f-PCT transmitted as an autosomal dominant trait, is characterized by photosensitive cutaneous lesions frequently associated to hepatic dysfunction and is precipitated by various ecogenic factors. The HEP, transmitted as a recessive trait, is more severe than f-PCT and would be considered as the homozygous form of f-PCT. For the mutational analysis of f-PCT patients, the entire URO-D gene was amplified and each exon, intron-exon boundaries and the promoter region were cycle sequenced. Five mutations were found in 6 unrelated families studied, of these, two were new: a nonsense mutation in exon 6 (W159X) and a splice defect in intron 9 (IVS9(-1)G-->C). The other two missense mutations, P62L and A80G, had been previously reported in the homozygous state in HEP families. The g10insA, reported in our laboratory, was again identified in other two unrelated families. In addition 3 novel URO-D polymorphisms in non-coding regions were found. The reverse transcription-PCR and sequencing of the splice mutation carrier's RNA did not reveal the presence of an abnormal mRNA, suggesting that no stable transcript from the mutated allele is synthesized. These results increase to 39 the number of mutations identified in the URO-D gene; 4 of them causing both HEP and f-PCT.
Asunto(s)
Mutación/genética , Porfiria Cutánea Tardía/genética , Porfiria Hepatoeritropoyética/enzimología , Porfiria Hepatoeritropoyética/genética , Uroporfirinógeno Descarboxilasa/deficiencia , Uroporfirinógeno Descarboxilasa/genética , Adulto , Argentina , Niño , Análisis Mutacional de ADN , Femenino , Humanos , Persona de Mediana Edad , Polimorfismo Genético/genética , Porfiria Hepatoeritropoyética/diagnósticoRESUMEN
Las porfirias son enfermedades metabólicas que surgen como consecuencia de una deficiencia enzimática parcial de alguna de las enzimas del hemo. En la porfiria Variegata (PV) este defecto se encuentra a nivel de la Protoporfirinógeno oxidasa (PPOX) quwe transforma el Protoporfirinógeno IX en Protoporfirina IX. Se caracteriza por presentar el síndromeagudo y cutáneo. Es una patología genéticamente heterogénea, al presente se han detectado 77 mutaciones diferentes en el gen de la PPOX, responsables de esta porfiria. Nuestro objetivo es el estudio bioquímico y molecular de pacientes con sintomatología de PV para llegar a un dignóstico certero de la enfermedad y hacerlo extensivo a sus familiares con el fin de identificar a los portadores asintomáticos y asesorarlos acerca del contacto con los factores desencadenantes de esta porfiria. Hasta el momento el estudio genético nos permitió detectar 2 mutaciones, una mutación puntual recientemente descripta que produce cambio de aminoácido, R168H en el exón 6 y una inserción nueva, 1320InT, que produce corrimiento del marco de lectura. Estos resultados han permitido confirmar el diagnóstico de PV en estos pacientes
Asunto(s)
Humanos , Porfirias Hepáticas/diagnóstico , Porfirias Hepáticas/genética , PorfirinasAsunto(s)
Sustitución de Aminoácidos/genética , Mutación Missense/genética , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Oxidorreductasas/genética , Porfirias Hepáticas/enzimología , Porfirias Hepáticas/genética , Flavoproteínas , Histidina/genética , Humanos , Leucina/genética , Proteínas Mitocondriales , Porfirias Hepáticas/diagnóstico , Prolina/genética , Protoporfirinógeno-Oxidasa , Valina/genéticaRESUMEN
Acute intermittent porphyria (AIP) is the most common type of hepatic acute porphyria. In this work, we have analyzed the biochemical data of all Argentinean AIP families studied in the Porphyrins and Porphyrias Research Centre (CIPYP). We have shown that: (i) the prevalence for this population is about 1:125,000; (ii) the disease is more frequent in women than in men (7:3); (iii) about 60% are latent carriers; (iv) 15% of patients with symptomatic AIP died during an acute attack; (v) the most important precipitating factors of acute attacks in our population were the ingestion of therapeutic drugs (25%), anesthetics in surgical interventions (25%) and infections (20%); (vi) the initial symptom in Argentinean AIP individuals is severe abdominal pain (100%), and it is often accompanied by constipation (37%), anorexia (37%) and tachycardia (30%); and (vii) the percentage of recurrence of the acute attacks is high (81%).
Asunto(s)
Porfiria Intermitente Aguda/metabolismo , Porfiria Intermitente Aguda/patología , Adulto , Argentina/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Porfiria Intermitente Aguda/epidemiología , Porfiria Intermitente Aguda/mortalidad , Prevalencia , Factores SexualesRESUMEN
A partial deficiency of Porphobilinogen deaminase (PBG-D) is responsible for acute intermittent porphyria (AIP). AIP is inherited in an autosomal dominant fashion, and the prevalence in the Argentinean population is about 1:125,000. Here, two new mutations and three previously reported were found in the PBG-D gene in 12 Argentinean AIP patients corresponding to 5 different families. To screen for AIP mutations in symptomatic patients, genomic DNA isolated was amplified in 2 Multiplex PCR reactions, then all coding exons and flanking intronic regions were sequenced. The new mutations are 453-455delAGC in exon 9 which results in the loss of an alanine residue at position 152, and one new point mutation in the splicing aceptor site in the last position of intron 8 (IVS8-1G>T) which leds to a 15 bp deletion because a cryptic site (first AG upstream) is used. Both mutations produce amino acid deletion without frameshift effect. To further characterize the 453-455delAGC mutation, the pKK-PBGD construct for the mutant allele was expressed in E. coli, the enzymatic activity of the recombinant protein was 1.3% of the mean level expressed by the normal allele. Finally, three missense mutations, previously reported, were identified in three unrelated families.
Asunto(s)
Hidroximetilbilano Sintasa/genética , Porfirias/genética , Adolescente , Adulto , Escherichia coli/enzimología , Femenino , Humanos , Hidroximetilbilano Sintasa/biosíntesis , Hidroximetilbilano Sintasa/metabolismo , Masculino , Persona de Mediana Edad , Mutación , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Acute intermittent porphyria (AIP), the most common hepatic porphyria, results from the half-normal activity of hydroxymethylbilane synthase (HMB-synthase; EC 4.3.1.8), the third enzyme in the heme biosynthetic pathway. Because life-threatening acute neurologic attacks of this autosomal dominant disease are triggered by various ecogenic factors (e.g., certain drugs, hormones, alcohol, and starvation), efforts have been directed to identify and counsel presymptomatic heterozygotes in affected families to avoid the precipitating factors. Thus, to determine the nature of the mutations causing AIP in 26 unrelated enzyme-confirmed patients from Argentina, a long-range polymerase chain reaction method was developed to amplify the entire 10-kb gene in two fragments for efficient cycle sequencing and mutation detection. Eight new mutations were identified including two missense mutations (Q34P and G335S), four small deletions (728delCT, 815delAGGA, 948delA, and 985del12), a single base insertion (666insA), and a splice site mutation (IVS12(+1)). In addition, five previously reported mutations (G111R, R173W, Q204X, R201W, and 913insC) were detected. Notably, G111R was identified in 12 of the 26 (46%) presumably unrelated propositi; however, haplotype analysis with intragenic and flanking markers indicated an ancestral founder. Expression of the two new missense mutations (Q34P and G335S) in f1 E. coli resulted in 2.5% or less of the normal expressed enzyme, confirming their defective function. Thus, eight new and five previously reported HMB-synthase mutations, including a common lesion, were detected, permitting accurate identification and counseling of presymptomatic carriers in these 26 unrelated Argentinean AIP families with this dominant porphyria.
Asunto(s)
Hidroximetilbilano Sintasa/genética , Mutación Puntual , Porfiria Intermitente Aguda/enzimología , Porfiria Intermitente Aguda/genética , Adolescente , Adulto , Argentina , Secuencia de Bases , Niño , Análisis Mutacional de ADN , Cartilla de ADN/genética , Escherichia coli/genética , Femenino , Efecto Fundador , Genes Dominantes , Asesoramiento Genético , Haplotipos , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Linaje , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo GenéticoRESUMEN
La porfiria cutánea tardía familiar (PCT-F) y la porfiria hepatoeritropoyética (PHE), son dos porfirias cutáneas causadas por la deficiencia en la actividad de la Uroporfirinógeno Decarboxilasa (URO-D), que es la quinta enzima del camino biosintético del hemo y cataliza la conversión del Uroporfirinógeno(UROgen) a Coproporfirinógeno (COPROgen). La PCT-F es dominante y la actividad de la URO-D está reducida a un 50 por ciento en todos los tejidos mientras que la PHE es recesiva y en ella la activcidad de la URO-D es sólo de un 5-10 por ciento del valor normal. El gen de la URO-D está compuesto por 10 exones dentro de 3 kb. Partiendo de 15 ml de sangre entera, y realizando separación de linfocitos, extracción de ARN, RT-PCR y secuenciación directa de las casi 1,2 del ADNc de la URO-D, se ha encontrado en un paciente argentina con PCT-F una mutación nueva caracterizada por la deleción del exón 9, La PCR y secuenciación del ADN genómico revelo que la deleción es causada por la transición G A en la última base del exón 9 que afecta la maduración ("splicing") del mensajero ya que inactivaría el sitio doner de "splicing" del intrón 9, como consecuencia se produce la unión entre el exón 8 y 10 lo cual a su vez lleva a un corrimiento de marco de lectura, que predice la síntesis de una proteína truncada con una perdida total de casi el 20 por ciento de sus aminoácidos
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Análisis Mutacional de ADN , Porfiria Cutánea Tardía , Uroporfirinógeno Descarboxilasa/deficienciaRESUMEN
Heme biosynthesis was studied in the segregants of Saccharomyces cerevisiae (DW10 tetrade 2) from D27 and D27/C6 mating, as a function of the carbon source in the growth medium and the physiological state of the cells. The effects of the HEM R+ gene on the 5-aminolevulinate synthase (ALA-S) and 5-aminolevulinate dehydratase (ALA-D) activities of heme biosynthesis in cells grown on nonfermentable and fermentable carbon sources were compared. Profiles obtained for both strains grown on a fermentable carbon source (glucose) were identical. However, in the presence of a nonfermentable carbon source (ethanol), they behave quite different, as if the mutation could only be expressed under these growth conditions. Moreover, their behavior is similar to that found for the parental strains, indicating that for the mutant its particular behavior might be inheritedly linked to the HEM R+ gene, which in turn affects some regulatory aspects of ALA synthesis explaining its characteristic phenotype.